JPRN-UMIN000024052已完成未知
Safety evaluation of an excessive consumption of Longvida - Safety evaluation of an excessive consumption of Longvida
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Subjects who have at least one previous medical history of malignant tumor, heart failure or myocardial infarction 2. Subjects who are patient or have history of cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases 3. Subjects who have undergone gastrointestinal tract surgery; except appendectomy 4. Subjects who are currently taking medicines (include herbal medicines) and/or supplements 5. Subjects who are allergic to medicines or the test material of this trial 6. Subjects who are or are possibly pregnant, or are lactating 7. Subjects who participate in other clinical trials in the past 3 months 8. Subjects who work time is irregular 9. Subjects who have been determined ineligible by principal investigator for other reasons
研究者
相似试验
已完成
不适用
Safety evaluation of excessive consumption of the test food to consume 5 times of regular daily intake in healthy subjectsHealthy Japanese subjectsJPRN-UMIN000036178ORTHOMEDICO Inc.11
已完成
不适用
Safety evaluation of excessive consumption of the test foodHealthy Japanese subjectsJPRN-UMIN000040823ORTHOMEDICO Inc.22
已完成
不适用
Safety evaluation of consumption of the test food in healthy subjectsHealthy Japanese subjectsJPRN-UMIN000036211ORTHOMEDICO Inc.14
已完成
不适用
Safety evaluation of an excessive consumption of a botanical extract-formulated food - Placebo control double blind parallel group comparison clinical trialhealthy subjectsJPRN-UMIN000030585Maruzen Pharmaceuticals Co., Ltd.52
已完成
不适用
Safety evaluation of an excessive consumption of a food containing botanical extract - Placebo control double blind parallel group comparison clinical trialhealthy subjectsJPRN-UMIN000030591Maruzen Pharmaceuticals Co., Ltd.52